Lupin will be responsible for the biosimilar鈥檚 manufacturing. Credit: MacroEcon/Shutterstock.

Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American markets, excluding Argentina and Mexico.

SteinCares will manage regulatory filings, registrations and commercialisation efforts for the biosimilar, while Lupin will be responsible for manufacturing.

The biosimilar is a recombinant humanised immunoglobulin G1 monoclonal antibody fragment that attaches and blocks vascular endothelial growth factor A.

It treats ocular conditions such as neovascular age-related macular degeneration, diabetic retinopathy, myopic choroidal neovascularisation and macular oedema following retinal vein occlusion.

Lupin聽Biotechnology president Dr Cyrus Karkaria stated: 鈥淥ur partnership with SteinCares underscores our commitment to providing innovative,聽high-quality healthcare solutions to patients in Latin America.

鈥淲e intend to transform the landscape of retinal care in Latin America,聽ensuring access to advanced therapies that improve the quality of life of patients.鈥�

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

SteinCares markets and distributes speciality healthcare products in the Latin American region, encompassing biosimilars, pharmaceuticals and complex generics. It operates in more than 30 nations there and the Caribbean.

SteinCares chief strategy officer Sebasti谩n Katz stated: 鈥淭his partnership with Lupin strengthens our portfolio and further reinforces SteinCares鈥� position as a biosimilar powerhouse in Latin America.

鈥淥ur presence has translated into significant cost savings for healthcare institutions, driven by decades of experience and a deep understanding of Latin America鈥檚 healthcare landscape.鈥�

Lupin recently received approval from the US Food and Drug Administration for the abbreviated new drug application for Rivaroxaban tablets USP with 10 mg, 15 mg and 20 mg doses, which are bioequivalent to Janssen 色界吧s’ Xarelto tablets. This product will be produced at Lupin鈥檚 Aurangabad facility in India.

In early 2025, Lupin secured approval from the agency for its Sacubitril and Valsartan tablets to treat heart failure.

色界吧 Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious 色界吧 Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now